Cibc World Markets Corp grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 16.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,611 shares of the medical instruments supplier's stock after purchasing an additional 6,414 shares during the period. Cibc World Markets Corp's holdings in Becton, Dickinson and Company were worth $10,348,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. Charles Schwab Investment Management Inc. increased its position in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier's stock worth $720,089,000 after purchasing an additional 1,317,723 shares during the period. First Eagle Investment Management LLC grew its holdings in shares of Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after acquiring an additional 1,057,879 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $181,279,000. Nordea Investment Management AB grew its holdings in shares of Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier's stock worth $647,082,000 after acquiring an additional 673,568 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier's stock worth $1,293,635,000 after acquiring an additional 460,440 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.
Insiders Place Their Bets
In related news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total value of $436,325.40. Following the transaction, the executive vice president now directly owns 7,411 shares of the company's stock, valued at approximately $1,666,808.01. This trade represents a 20.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the transaction, the executive vice president now directly owns 16,201 shares in the company, valued at $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,984 shares of company stock valued at $1,147,865 in the last quarter. 0.36% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
BDX has been the topic of a number of research reports. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, March 5th. Piper Sandler upped their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a report on Tuesday, January 28th. Finally, Barclays upped their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $278.29.
View Our Latest Report on Becton, Dickinson and Company
Becton, Dickinson and Company Price Performance
BDX stock traded down $1.22 on Friday, reaching $230.63. The company had a trading volume of 4,372,181 shares, compared to its average volume of 1,539,839. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a market cap of $66.22 billion, a P/E ratio of 38.31, a PEG ratio of 1.63 and a beta of 0.35. The company's fifty day moving average is $232.58 and its 200 day moving average is $232.04. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its shares are undervalued.
Becton, Dickinson and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is presently 69.10%.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
